Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1766818

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1766818

France Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

PUBLISHED:
PAGES: 153 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4995
PDF (Site License)
USD 9990
PDF (Global License)
USD 14985

Add to Cart

GlobalData's "France Oncology Market Outlook to 2033" is a comprehensive databook report, covering key market data on the France Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The France Oncology Market report provides key information and data on -

  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
  • 2024 company share data for Oncology Market.
  • Global corporate-level profiles of key companies operating within the France Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

France Oncology is segmented as follows -

  • Colorectal Cancer Screening Tests
  • EGFR Tests
  • KRAS Tests
  • HER2 Tests
  • BRCA Tests
  • ALK Tests
  • BRAF Tests
  • BCR-ABL Tests
  • PD-L1 Tests

Reasons to Buy

The France Oncology Market report helps you to develop -

  • Business strategies by identifying the key market segments poised for strong growth in the future.
  • Market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.
Product Code: GDME25621CCDB

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 What Is This Report About?
  • 2.2 Oncology Market Segmentation
  • 2.3 Definitions of Markets Covered in the Report

3 Oncology Market, France

  • 3.1 Oncology Market, France, Revenue ($m), 2018-2033
    • 3.1.1 ALK Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.2 BCR-ABL Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.3 BRAF Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.4 BRCA Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.5 Colorectal Cancer Screening Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.6 EGFR Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.7 HER2 Tests Market, France, Revenue ($m), by Segment, 2018-2033
    • 3.1.8 KRAS Tests Market, France, Revenue ($m), by Segment, 2018-2033
  • 3.2 Oncology Market, France, Volume (Units), 2018-2033
    • 3.2.1 ALK Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.2 BCR-ABL Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.3 BRAF Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.4 BRCA Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.5 Colorectal Cancer Screening Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.6 EGFR Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.7 HER2 Tests Market, France, Volume (Units), by Segment, 2018-2033
    • 3.2.8 KRAS Tests Market, France, Volume (Units), by Segment, 2018-2033
  • 3.3 Oncology Market, France, Average Price ($) , 2018-2033
  • 3.4 Oncology Market, France, Company Share by Revenue ($m), 2024

4 Overview of Key Companies in France, Oncology Market

  • 4.1 F. Hoffmann-La Roche Ltd
    • 4.1.1 Company Overview
  • 4.2 Agilent Technologies Inc
    • 4.2.1 Company Overview
  • 4.3 Abbott Laboratories
    • 4.3.1 Company Overview
  • 4.4 Qiagen NV
    • 4.4.1 Company Overview
  • 4.5 Danaher Corp
    • 4.5.1 Company Overview
  • 4.6 Eiken Chemical Co Ltd
    • 4.6.1 Company Overview
  • 4.7 Resonac Corporation
    • 4.7.1 Company Overview
  • 4.8 Alfresa Pharma Corp
    • 4.8.1 Company Overview
  • 4.9 Hemosure Inc
    • 4.9.1 Company Overview
  • 4.10 SENTINEL CH SpA
    • 4.9.1 Company Overview

5 Oncology Market Pipeline Products

6 Financial Deals Landscape

  • 6.1 Equity Offerings
    • 6.1.1 Ikonisys Raises USD0.16 Million in Private Placement of Shares
    • 6.1.2 Phaxiam Therapeutics Raises USD8.39 Million in Private Placement of Shares
  • 6.2 Partnerships
    • 6.2.1 A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix
  • 6.3 Private Equity
    • 6.3.1 Consortium of Investor to Acquire Eurobio Scientific
  • 6.4 Venture Financing
    • 6.4.1 HEPTA Medical Raises USD6.29 Million in Series A Financing
    • 6.4.2 Spotlight Medical Raises USD6.72 Million in Seed Financing

7 Recent Developments

  • 7.1 Corporate Communications
    • 7.1.1 Feb 11, 2025: UK-backed AI Companies to Transform British Cancer Care and Spark New Drug Breakthroughs
    • 7.1.2 Oct 03, 2024: Successful 2024 ISO 13485 Certification Maintenance Strengthening Ikonisys' Strong Market Position and Growth Potential
  • 7.2 Government and Public Interest
    • 7.2.1 Apr 14, 2025: Tackling Vulnerabilities in the Supply Chain of Radiopharmaceuticals in the EU
  • 7.3 Other Significant Developments
    • 7.3.1 Jan 06, 2025: PhenoVista Biosciences Partners with NETRI to Expand Organ-on-Chip Service Offerings for Drug Development
    • 7.3.2 Nov 12, 2024: Ikonisys Group Renews Agreement as European Authorized Representative and Importer for Novodiax's CE IVD-Certified Technology in Oncological Diagnostics and Organ Transplant Safety
    • 7.3.3 Oct 31, 2024: CURE51 Chooses 10X Genomics Visium HD for New Drug Discovery Initiative
    • 7.3.4 Sep 17, 2024: Precision Microbiome Profiling Demonstrates It Diagnostic Potential in Groundbreaking Work Conducted at Gustave Roussy Cancer Institute
  • 7.4 Product News
    • 7.4.1 Apr 08, 2025: Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM
    • 7.4.2 Jan 20, 2025: Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing From Exploratory Research to Clinical Trials
    • 7.4.3 Dec 03, 2024: The Ikonisys Group Unveils its New Vision and Strategy Under the Brand "ALIKO SCIENTIFIC"
    • 7.4.4 Nov 21, 2024: Prestigious Cancer Center Institut Curie Introduces Ibex Medical Analytics' AI Tools for Cancer Diagnostics
    • 7.4.5 Aug 26, 2024: Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
  • 7.5 Strategy And Business Planning
    • 7.5.1 Feb 26, 2025: OncoHost Announces Collaboration With Gustave Roussy
    • 7.5.2 Jan 06, 2025: PhenoVista Biosciences Partners with NETRI to Expand Organ-on-Chip Service Offerings for Drug Development
    • 7.5.3 Nov 25, 2024: French Hospital Joins Regional Pathology Solution From Sectra to Enhance Collaboration and Speed Up Cancer Diagnostics
    • 7.5.4 Sep 24, 2024: Curium Opens Additional and New Facility in Petten, Netherlands
    • 7.5.5 Jun 27, 2024: Spotlight Medical Emerges from Stealth to Tackle the Critical Issue of Inadequate Cancer Treatments

8 Appendix

  • 8.1 Research Methodology
    • 8.1.1 Coverage
    • 8.1.2 Secondary Research

sssssss8.1.3 Primary Research

    • 8.1.4 Market Modeling and Forecasting
    • 8.1.5 Company Share Analysis
    • 8.1.6 Benchmarking
  • 8.2 GlobalData Consulting
  • 8.3 Contact Us
  • 8.4 Disclaimer
Product Code: GDME25621CCDB

List of Table

List of Tables

  • Table 1: Oncology Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 2: ALK Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 3: BCR-ABL Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 4: BRAF Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 5: BRCA Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 6: Colorectal Cancer Screening Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 7: EGFR Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 8: HER2 Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 9: KRAS Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Table 10: Oncology Market, France, Volume (Units), 2018-2033
  • Table 11: ALK Tests Market, France, Volume (Units), 2018-2033
  • Table 12: BCR-ABL Tests Market, France, Volume (Units), 2018-2033
  • Table 13: BRAF Tests Market, France, Volume (Units), 2018-2033
  • Table 14: BRCA Tests Market, France, Volume (Units), 2018-2033
  • Table 15: Colorectal Cancer Screening Tests Market, France, Volume (Units), 2018-2033
  • Table 16: EGFR Tests Market, France, Volume (Units), 2018-2033
  • Table 17: HER2 Tests Market, France, Volume (Units), 2018-2033
  • Table 18: KRAS Tests Market, France, Volume (Units), 2018-2033
  • Table 19: Oncology Market, France, Average Price ($), 2018-2033
  • Table 20: Oncology Market, France, Company Share by Revenue ($m), 2024
  • Table 21: Oncology Market Pipeline Products
  • Table 22: Ikonisys Raises USD0.16 Million in Private Placement of Shares
  • Table 23: Phaxiam Therapeutics Raises USD8.39 Million in Private Placement of Shares
  • Table 24: A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix
  • Table 25: Consortium of Investor to Acquire Eurobio Scientific
  • Table 26: HEPTA Medical Raises USD6.29 Million in Series A Financing
  • Table 27: Spotlight Medical Raises USD6.72 Million in Seed Financing
  • Table 28: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

List of Figure

List of Figures

  • Figure 1: Oncology Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 2: ALK Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 3: BCR-ABL Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 4: BRAF Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 5: BRCA Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 6: Colorectal Cancer Screening Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 7: EGFR Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 8: HER2 Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 9: KRAS Tests Market, France, Revenue ($m), USD Constant, 2018-2033
  • Figure 10: Oncology Market, France, Volume (Units), 2018-2033
  • Figure 11: ALK Tests Market, France, Volume (Units), 2018-2033
  • Figure 12: BCR-ABL Tests Market, France, Volume (Units), 2018-2033
  • Figure 13: BRAF Tests Market, France, Volume (Units), 2018-2033
  • Figure 14: BRCA Tests Market, France, Volume (Units), 2018-2033
  • Figure 15: Colorectal Cancer Screening Tests Market, France, Volume (Units), 2018-2033
  • Figure 16: EGFR Tests Market, France, Volume (Units), 2018-2033
  • Figure 17: HER2 Tests Market, France, Volume (Units), 2018-2033
  • Figure 18: KRAS Tests Market, France, Volume (Units), 2018-2033
  • Figure 19: Oncology Market, France, Company Share (%), 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!